NoemaLife Leader in Healthcare IT

Flash is required!

2011: NoemaLife increases its turnover and bets on new products

Thursday, 16 March 2012 - The Board of Directors of NoemaLife, chaired by Paolo Toth, approved the parent company and Consolidated Financial Statements for 2011.
In 2011, total Consolidated Revenues amounts to EUR 48.5 million, up 13% against the previous year. EBITDA is EUR 9.1 million, up compared to EUR 7.6 million recorded in 2010. Group EBIT is around EUR 3.4 million and Consolidated Net Profit for the year is EUR 1.4 million.
Investments for the development of new products in 2011 amounts to EUR 5.1 million, corresponding to around 11% of operating revenues. The net financial position as at 31 December 2011 is EUR -37.6 million, because of the acquisition transactions of  Medasys, Solinfo e ConnexxaLife in 2011.
The results achieved in 2011 provide a strong basis for the Group’s commitment to expand its business in the near time. In 2012 NoemaLife continues to own strategy position as a product company that constantly invests on the innovation and growth of its products, which are strategic for the management. 

Customer Satisfaction 2011

Customer service lies at the core of NoemaLife’s operations. The excellent results of the 2011 Customer Satisfaction survey confirm the highest level of service and quality delivered by the team of expert and specialized professionals of the NoemaLife Group.

The overall average evaluation scored in the period of Italian NoemaLife customers is 3.71 (next to ‘very satisfied’). Interviewed customers expressed a high degree of satisfaction, in particular for: NoemaLife’s solutions Reliability, Technicians competence and responsibility and the quality of Customer Service.

 

HALIA: The complete Solution for Lab Automation

HALIA instrument middleware from NoemaLife provides a complete lab computerisation solution. HALIA lets you manage centrally all the pre-analysis, analysis and postanalysis instruments found in a modern clinical lab.